<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Acta Naturae</journal-id><journal-title-group><journal-title xml:lang="en">Acta Naturae</journal-title><trans-title-group xml:lang="ru"><trans-title>Acta Naturae</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-8251</issn><publisher><publisher-name xml:lang="en">Acta Naturae Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10409</article-id><article-id pub-id-type="doi">10.32607/20758251-2017-9-1-105-107</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Short communications</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Краткие сообщения</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Antiretroviral Activity Of a Novel Pyrimidyl-Di(Diazaspiroalkane) Derivative</article-title><trans-title-group xml:lang="ru"><trans-title>Антиретровирусная активность нового производного пиримидил-ди(диазодиспироалкана)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Novoselova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Новоселова</surname><given-names>E. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>helen.novoselova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Riabova</surname><given-names>O. B.</given-names></name><name xml:lang="ru"><surname>Рябова</surname><given-names>O. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>helen.novoselova@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Leneva</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Ленева</surname><given-names>И. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>helen.novoselova@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nesterenko</surname><given-names>V. G.</given-names></name><name xml:lang="ru"><surname>Нестеренко</surname><given-names>В. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>helen.novoselova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bolgarin</surname><given-names>R. N.</given-names></name><name xml:lang="ru"><surname>Болгарин</surname><given-names>Р. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>helen.novoselova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Makarov</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Макаров</surname><given-names>В. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>helen.novoselova@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">«NEARMEDIC PLUS» LLC</institution></aff><aff><institution xml:lang="ru">ООО «НИАРМЕДИК ПЛЮС»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Federal Research Centre «Fundamentals of Biotechnology» of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Федеральный исследовательский центр «Фундаментальные основы биотехнологии» РАН</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I.Mechnikov Research Institute of Vaccines and Sera</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2017</year></pub-date><volume>9</volume><issue>1</issue><issue-title xml:lang="en">VOL 9, NO1 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 9, №1 (2017)</issue-title><fpage>105</fpage><lpage>107</lpage><history><date date-type="received" iso-8601-date="2020-01-17"><day>17</day><month>01</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Novoselova E.A., Riabova O.B., Leneva I.A., Nesterenko V.G., Bolgarin R.N., Makarov V.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Новоселова E.A., Рябова O.Б., Ленева И.A., Нестеренко В.Г., Болгарин Р.Н., Макаров В.A.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Novoselova E.A., Riabova O.B., Leneva I.A., Nesterenko V.G., Bolgarin R.N., Makarov V.A.</copyright-holder><copyright-holder xml:lang="ru">Новоселова E.A., Рябова O.Б., Ленева И.A., Нестеренко В.Г., Болгарин Р.Н., Макаров В.A.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://actanaturae.ru/2075-8251/article/view/10409">https://actanaturae.ru/2075-8251/article/view/10409</self-uri><abstract xml:lang="en"><p>A novel compound, 3,3’-(5-nitropyrimidine-4,6-diyl)bis-3,12-diaza-6,9-diazoniadispiro[5.2.5.2]hexadecane tetrachloride dihydrochloride, was synthesized. The compound was found to inhibit the replication of various viral families by blocking specific heparan sulfate receptors on the host cell’s surface. In experiments, the compound was found to be highly effective against several strains of HIV retroviruses.</p></abstract><trans-abstract xml:lang="ru"><p>Синтезирован 3,3’-(2-метил-5-нитропиримидин-4,6-диил)бис-3,12-диаза-6,9-диазониа-диспиро[5.2.5.2]гексадекан тетрахлорид дигидрохлорида, соединение, ингибирующее репликацию вирусов различных семейств, использующих гепарансульфатпротеогликаны для прикрепления к клетке хозяина. Это соединение показало высокую эффективность в отношении ряда штаммов ВИЧ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>antiviral activity</kwd><kwd>dispiro compounds</kwd><kwd>heparan sulfate</kwd><kwd>HIV</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>HIV</kwd><kwd>ВИЧ</kwd><kwd>гепарансульфат</kwd><kwd>диспиросоединения</kwd><kwd>противовирусная активность</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>[1] Shukla D., Spear PG. // J.Invest. 2001, V.108, №4, P.503-510</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>[2] Selinka HC., Giroglou T. // Sapp 2002, V.299, №2, P.279-287</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>[3] Paeschke R., Woskobojnik I. // MakarovAgents Chemother. 2014, V.58, №4, P.1963-1971</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>[4] Patel V., Ferguson M. // Minor 1993, V.192, №1, P.361-364</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>[5] Hallak LK., Spillmann D. // Collins. 2000, V.74, №22, P.10508-10513</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>[6] Jiang YF., He B. // MaBelg. 2012, V.75, №3, P.316-321</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>[7] Schmidtke M., Wutzler P. // MakarovDrug Design &amp; Discovery. 2004, V.1, №4, P.293-299</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>[8] Artemenko AG., Muratov EN. // Kuz’min 2007, V.60, №1, P.68-77</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>[9] Kaminka M.E., Kalinkina M.A., Pushkina T.V., Tupikina S.M., Ryabova O.B., Makarov V.A., Granik V.G. // Eksp. i Klin. Farmakol. 2004, V.67, №3, P.30-33</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>[10] Weislow OS., Kiser R. // FineCancer Inst. 1989, V.81, №8, P.577-586</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>[11] O’Brien SJ., Moore JP. // ImmunolRev. 2000, V.177, P.99-111</mixed-citation></ref></ref-list></back></article>
